Buch, Englisch, 550 Seiten, Format (B × H): 191 mm x 235 mm
Buch, Englisch, 550 Seiten, Format (B × H): 191 mm x 235 mm
ISBN: 978-0-443-27429-9
Verlag: Elsevier Science
Harnessing Endogenous Mechanisms for Targeted Drug Delivery explores the cutting-edge advancements in the world of targeted drug delivery leveraging human biological mechanisms. This essential guide addresses the urgent need to enhance the efficiency of drug delivery and foster safe and effective therapies, particularly for biological agents like proteins, peptides, and nucleic acid molecules. The book offers a comprehensive exploration of tissue- and cell-specific delivery methods, emphasizing endogenous or biological techniques that can be utilized to improve drug delivery. It identifies the challenges associated with delivering complex molecules and accessing hard-to-reach sites, and provides practical solutions through endogenous strategies. Topics such as exploiting disease-specific stimuli to enhance delivery efficiency, the role of plasma proteins in drug delivery, and the utilization of extracellular vesicles to boost delivery efficiency are presented. Harnessing Endogenous Mechanisms for Targeted Drug Delivery emphasizes the clinical and commercial translation of these techniques, making this book an ideal resource for researchers, clinicians, and anyone interested in the future of drug delivery.
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Section 1: Drug Delivery Challenges and Opportunities
1. Contemporary Drug Delivery Challenges
2. Delivery Barriers
3. Strategies for Targeted Drug Delivery
Section 2: Endogenous Strategies
4. Stimuli-Responsive Delivery
5. Glyco-Targeting using Lectins
6. Delivery using Plasma Proteins or Endogenous Peptides
7. Utilizing Virus Engineering in Drug Delivery
8. Living or artificial Cells as Trojan Horse-Cloaking Particles
9. Augmenting Cellular Cargo Capacity
10. Cell- and Bacterial-Derived Extracellular Vesicles-Based Targeted Delivery
11. Nucleic acid based delivery systems
Section 3: Clinical Translation
13. Challenges Associated with Endogenous Targeting - Preclinical to clinical, scalability, toxicity
14. Current Clinical Trials
15. Clinical and Commercial Translational Challenges